67N0.F GENOR BIOPHARMA DL-00002
- Market cap
- EUR 95.7M
- P/E
- 17.1x
- P/B
- 1.32x
- ROE
- -4.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is 67N0.F undervalued?
Graham number67N0.F trades 0.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GENOR BIOPHARMA DL-00002 fundamental analysis
No fundamental analysis for GENOR BIOPHARMA DL-00002 yet.
GENOR BIOPHARMA DL-00002 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GENOR BIOPHARMA DL-00002
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidat…
Full company profileGENOR BIOPHARMA DL-00002 financial statements
GENOR BIOPHARMA DL-00002 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 15.9M | 0.00 | 206M |
| Gross Profit | 0.00 | 14.9M | 0.00 | 205M |
| Operating Income | -919M | -786M | -686M | -32.7M |
| EBITDA | -803M | -676M | -600M | -16.8M |
| Net Income | -865M | -730M | -674M | -51.3M |
| EPS | -1.72 | -1.46 | -1.34 | -0.10 |
| Balance Sheet | ||||
| Total Assets | 2.86B | 2.12B | 1.45B | 1.29B |
| Total Liabilities | 370M | 310M | 256M | 138M |
| Shareholders' Equity | 2.49B | 1.80B | 1.19B | 1.15B |
| Cash & Short-term Investments | 2.20B | 1.59B | 1.17B | 1.06B |
| Cash Flow | ||||
| Operating Cash Flow | -624M | -578M | -425M | -122M |
| Capital Expenditure | 71.4M | 13.0M | 1.03M | 1.57M |
| Free Cash Flow | -695M | -591M | -426M | -124M |
| Ratios | ||||
| ROE | -34.7% | -40.5% | -56.7% | -4.5% |
| ROA | -30.2% | -34.5% | -46.6% | -4.0% |
| Net Profit Margin | - | -4,583.3% | - | -24.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GENOR BIOPHARMA DL-00002 dividends
GENOR BIOPHARMA DL-00002 has not paid dividends in the last 4 fiscal years.
Who owns GENOR BIOPHARMA DL-00002
- Insiders 47.46%
- Institutions 25.91%
- Public & others 26.64%
- Shares outstanding 525M
- Free float 711M
GENOR BIOPHARMA DL-00002 company profile
- Company name
- GENOR BIOPHARMA DL-00002
- Ticker
- 67N0.F
- ISIN
- KYG3871A1004
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,499
- Fiscal year end
- December
- Address
- Building 1, Zhuhai, China
- Phone
- 86 21 6169 0700
- Website
- eddingpharm.com
About GENOR BIOPHARMA DL-00002
Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for multidrug-resistant gram-positive bacteria; Ceclor for mild to moderate community-acquired bacterial infections in children; Yirui Ping for nebulized inhalation therapy; Vascepa for cardiovascular risk reduction; Mulpleta for reducing bleeding risk; Jing Zhu Da for breast cancer treatment; Recormon for CRA indication; and three siRNA candidates for chronic disease treatment, as well as entinostat and lerociclib hydrochloride tablets. In addition, the company is involved in marketing, commercialization, and trading of pharmaceutical products; research and development of respiratory products; and consultancy and promotion services. Its products are used in oncology, autoimmune, cardiovascular, respiratory, and anti-infective therapeutic areas. Edding Genor Group Holdings Limited was founded in 2001 and is headquartered in Zhuhai, China.
GENOR BIOPHARMA DL-00002 management
7- Mr. Xin NiChief Executive Officer & Executive Chairman · born 1972
- Dr. Shuhua Han Ph.D.Chief Scientific Officer & Executive Director · born 1959
- Mr. Chen ZiExecutive Vice President · born 1972
- Mr. Zhibing WengSenior Vice President · born 1980
- Ms. Hanqing XieSenior Vice President · born 1981
- Ms. Qianhui WangJoint Company Secretary · born 1990
- Ms. Chui Mei YipJoint Company Secretary